BRIEF-Exelixis Announces Update On Second Patent Litigation Trial With MSN Laboratories

Reuters
16 Oct 2024

Oct 15 (Reuters) - Exelixis Inc :

* EXELIXIS ANNOUNCES UPDATE ON SECOND PATENT LITIGATION TRIAL WITH MSN LABORATORIES

* EXELIXIS INC - U.S. COURT RULES IN EXELIXIS' FAVOR IN PATENT LITIGATION AGAINST MSN

* EXELIXIS INC - EARLIEST MSN CAN LAUNCH GENERIC CABOZANTINIB IN U.S. IS JAN 15, 2030

* EXELIXIS INC - FDA HAS NOT YET GRANTED TENTATIVE APPROVAL FOR MSN'S GENERIC CABOZANTINIB

* EXELIXIS INC - COURT RULED CO'S PHARMACEUTICAL COMPOSITION PATENT NOT INVALID, NOT INFRINGED BY MSN

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10